

AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the application:

LISTING OF CLAIMS:

1-21. (canceled)

22. (new) A method for treating a patient with a pathology selected from the group consisting of malignant hemopathies and solid tumors, wherein said patient is resistant to, or at risk of developing a resistance to a NF- κ B-activating cytotoxic molecule which is administered to said patient in the scope of the treatment of said pathology, comprising administering to said patient an effective amount of human growth hormone comprising SEQ ID NO: 2.

23. (new) The method according to claim 22, wherein the human growth hormone is encoded by SEQ ID NO: 1.

24. (new) The method according to claim 22, wherein the cytotoxic molecule is an anthracycline.

25. (new) The method according to claim 22, wherein the cytotoxic molecule is paclitaxel.

26. (new) The method according to claim 22, wherein the cytotoxic molecule is an anthracycline and the dosage of said anthracycline administered with said growth hormone is about 2 to about 5 times less than the dosage of said anthracycline

administered alone in the scope of the treatment of said pathology.

27. (new) The method according to claim 22, wherein the cytotoxic molecule is paclitaxel and the dosage of paclitaxel administered with said growth hormone is about 2 to about 5 times less than the dosage of paclitaxel administered alone in the scope of the treatment of said pathology.